Homeopathic Medicinal Products Working Group (HMPWG)
Introduction
European group dedicated to homeopathic medicinal products for human and veterinary use
Mandate
- To create a forum for exchange of regulatory and scientific expertise regarding the assessment of the quality, safety and homeopathic use of homeopathic medicinal products for human and veterinary use;
- To provide guidance on the assessment of homeopathic medicinal products on request from Competent Authorities;
- To provide guidance for applicants on the registration of homeopathic medicinal products;
- To establish one common dossier template for applications for the registration (Article 14 of Directive 2001/83/EC, as amended) of homeopathic medicinal products in the EU, in co-operation with the Notice to Applicants Group;
- To provide advice and expertise on request of the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMD(h)) and Co-ordination Group for Mutual Recognition and Decentralised Procedures - Veterinary (CMD(v)) on procedural, regulatory and scientific issues arising from the mutual recognition and decentralised procedures applicable to homeopathic medicinal products;
- To facilitate the resolution of procedural, regulatory, and scientific issues arising from variation procedures pertaining to homeopathic medicinal products;
- To support the drafting of a list of safe dilution grades for homeopathic medicinal products;
- To address regulatory and scientific issues concerning homeopathic medicinal products on request by the European Commission, the CMD(h), the CMD(v), the Heads of Medicines Agencies and the EDQM;
- To draft rules of procedure for approval by the Heads of Medicines Agencies;
- To prepare guidance documents which will be presented to the Heads of Medicines Agencies for publication on their website;
- To ensure reporting for the Heads of Medicines Agencies.
Rules of Procedure
HMPWG's Rules of Procedure | pdf
Document adopted at HMA meeting in Dublin 30/01/2013, as amended by HMPWG at the 23rd meeting in Utrecht 14-15/04/2016, the 29th meeting in Bucharest 23-24/05/2019, the 34th meeting in Paris 12-13/05/2022, by written procedure on 15/9/2022, and the 38th meeting in Bruges 25-26/6/2024
- The HMPWG is composed of representatives from the National Competent Authorities (NCAs) and a veterinarian representative . Representatives of the European Commission (EC) and European Medicines Agency (EMA) are invited to attend all meetings of the HMPWG. Observers from European Directorate for the Quality of Medicines and Healthcare (EDQM), the EFTA countries and the World Health Organisation (WHO) may also participate.
- Meeting cycle: 2 meetings/year, once per EU presidency
- Chair: Awaiting election
Contact Point:HMPWG-Secretariat @ hma .eu
- Template for submission of request to HMPWG | word
Adopted by HMPWG on 18 October 2018 - Guidance document on submission of request to the HWPWG | pdf
Adopted by HMPWG on 31 May 2018
Reports from meetings
- 18 October 2023, Virtual, Vienna (Austria): report | pdf
Adopted in June 2024 - 29-30 March 2023, Uppsala (Sweden): report | pdf
Adopted in October 2023 - 27-28 October 2022, Rome (Italy): report | pdf
Adopted in March 2023 - 12-13 May 2022, Paris (France): report | pdf
Adopted in October 2022 - 10 November 2021, Ljubljana (Slovenia): report | pdf
Adopted by written procedure in January 2022 - 28 January 2021, Lisbon (Portugal): report | pdf
Adopted by written procedure in April 2021 - 01-02 September 2020, Bonn (Germany) report | pdf
Adopted by written procedure in October 2020 - 24-25 October 2019, Bucharest (Romania): report | pdf
Adopted by written procedure in December 2019 - 23-24 May 2019, Bucharest (Romania): report | pdf
Adopted in October 2019 - 18-19 Oct 2018, Vienna (Austria): report | pdf
Adopted by written procedure in February 2019 - 17-18 May 2018, Berlin (Germany): report | pdf
- 5-6 December 2017, Uppsala (Sweden): report | pdf
- 26-27 June 2017, Gozo (Malta): report | pdf
- 10-11 November 2016, Bern (Switzerland): report | pdf
Adopted by written procedure in January 2017 - 14-15 April 2016, Utrecht (The Netherlands): report | pdf
Adopted by written procedure in June 2016 - 11-12 November 2015, Utrecht (The Netherlands): report | pdf
Adopted by written procedure in January 2016 - 28-29 May 2015, Strasbourg (France): report | pdf
- 4-5 December 2014, Rome (Italy): report | pdf
- 5-6 June 2014, Paris (France): report | pdf
Revision to Public Report | pdf - 21-22 November 2013, Bonn (Germany): report | pdf
- 30-31 May 2013, Dublin (Ireland): report | pdf
- 23 October 2012, Gdansk (Poland): report | pdf
- 5-6 June 2012, Copenhagen (Denmark): report | pdf
- 7-8 June 2011, Budapest (Hungary): report | pdf
Other reports
- HMPWG Report on the Regulatory Status of Homeopathic Medicinal Products for Human Use in EU/EEA Countries – Update – 2022 | pdf
Adopted by consensus at the 36th HMPWG meeting (29-30 March 2023) under the Swedish Presidency - HMPWG Report on the Regulatory Status of Homeopathic Medicinal Products for Human Use in EU And EFTA Countries | pdf
Adopted by written procedure in February 2017
Documents for public consultation
1. Guidance on module 3 of the homeopathic medicinal products dossier_rev.1
Deadline for comments 4 October 2024. Interested parties are invited to submit their comments to HMPWG-Secretariat @ hma .eu
Deadline for comments 4 October 2024. Interested parties are invited to submit their comments to HMPWG-Secretariat @ hma .eu
Templates for public consultations
- Template for submission of comments on draft document | doc
Adopted November 2013
General Guidance
- List of Terms used in Homeopathic Medicinal Products | pdf
Adopted by HMA 27 November 2014
Regulatory and Legal Issues
- Questions and answers document on regulatory and legal issues concerning homeopathic medicinal products in the European framework | pdf
Final confirmation on Revision 1 from the European Commission 27 March 2024
Notice to Applicants
- Notice to Applicants Volume 2B Module 1 - Homeopathic application form | doc
Revised December 2016 - Eudralex website
Quality
- Mandate of sub-Working Group on Quality | pdf
Adopted by HMA MG on 2 February 2016 - Work Programme of sub-Working Group on Quality | pdf
Adopted by HMA MG on 2 February 2016
Homeopathic Use
- Mandate of the Homeopathic Use sub-group | pdf
Adopted November 2015
First Safe Dilutions
- FSD Sub-working group Mandate | pdf
Adopted June 2024 - FSD Sub-working group General Work Programme | pdf
Adopted May 2013
The documents in this section are also valid for veterinary homeopathic medicinal products as far as applicable.
Guidance documents
- Guidance on module 3 | pdf
November 2007 - Guidance on module 3.2.S for Nosodes | pdf
Adopted by HMPWG October 2018 - Points to Consider on selection of Microbial limits for non-sterile homeopathic raw materials, stocks, preparations and products | pdf
Adopted by HWPWG June 2017 - Points to consider on Stability Testing of HMPs | pdf
Approved by HMPWG July 2009
Questions and answers
- Questions and Answers document on the quality of homeopathic medicinal products (Q 1-2)_raw materials
Adopted by HMPWG on 23-24 May 2019 - Questions and Answers document on the quality of homeopathic medicinal products (Q 3)_raw materials
Adopted by HMPWG on 15 November 2019 - Questions and Answers document on the quality of homeopathic medicinal products (Q 4-5)_stability_manufacturing
Adopted by HMPWG on 23-24 May 2019 - Questions and Answers document on the quality of homeopathic medicinal products (Q 6-7)_process validation_specification and testing
Adopted by HMPWG on 23-24 May 2019 - Questions and Answers document on the quality of homeopathic medicinal products (Q 8)_manufacturing
Adopted by HMPWG on 23-24 May 2019 - Questions and Answers document on the quality of homeopathic medicinal products (Q 9)_GMP compliance
Adopted by HMPWG on 27-28 October 2022 - Questions and Answers document on the quality of homeopathic medicinal products (Q 10)_microbiological quality
Adopted by HMPWG on 23-24 May 2019 - Questions and Answers document on the quality of homeopathic medicinal products (Q 11-12)_impurities
Adopted by HMPWG on 23-24 May 2019 - Questions and Answers document on the quality of homeopathic medicinal products (Q 13)_stability
Adopted by HMPWG on 27-28 October 2022
Overview of comments
- Overview of comments on Guidance for Nosodes | pdf
Adopted by HMPWG October 2018 - Overview of comments received on draft document "Points to Consider on Selection of Microbial Limits for Non-sterile Homeopathic Raw Materials, Stocks, Preparations and Products" | pdf
Adopted by HWPWG June 2017 - Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 1-2)
Adopted by HMPWG on 23-24 May 2019 - Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 3)
Adopted by HMPWG on 15 November 2019 - Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 4-5)
Adopted by HMPWG on 23-24 May 2019 - Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 6-7)
Adopted by HMPWG on 23-24 May 2019 - Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 8)
Adopted by HMPWG on 23-24 May 2019 - Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 9)
Adopted by HMPWG on 27-28 October 2022 - Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 10)
Adopted by HMPWG on 23-24 May 2019 - Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 11-12)
Adopted by HMPWG on 23-24 May 2019 - Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 13)
Adopted by HMPWG on 27-28 October 2022
Guidance documents
- Points to consider on the justification of homeopathic use of stock (June 2012) | pdf
- Preamble to the consolidated list of justified homeopathic stocks | pdf
Adopted May 2018 - Consolidated list of stocks for which homeopathic use is justified | pdf
Adopted May 2018
This is a final comprehensive document of the previous adopted lists 1-6, sorted alphabetically by the GHP/German traditional name of the stock. - Consolidated list of stocks for which homeopathic use is justified | pdf
Adopted May 2018
This is a final comprehensive document of the previous adopted lists 1-6, sorted alphabetically by the FP/French traditional name of the stock.
Overview of comments
- Overview of comments received on the draft version of the preamble | pdf
Adopted May 2018 - Overview of comments received on the draft version of the Sixth list | pdf
Adopted May 2018 - Overview of comments received on the draft version of the Fifth list | pdf
Adopted June 2017 - Overview of comments received on draft version of the Fourth list | pdf
Adopted November 2016 - Overview of the comments received on Preamble to the consolidated list of justified stocks | pdf
Adopted June 2016 - Overview of comments received on draft version of the Third list | pdf
Adopted May 2015 - Overview of comments received on draft version of the Second list | pdf
Adopted December 2014 - Answer of the HMPWG to the stakeholders after the public consultation on the First list | pdf
Guidance Documents
- Guidance on non-clinical documentation in applications for registration of homeopathic medicinal products for human use | pdf
Adopted November 2021 - Points to consider on non-clinical safety of homeopathic medicinal products of botanical, mineral and chemical origin | pdf
July 2007 (Status: superseded by Guidance on non-clinical documentation) - Points to Consider on Safety of Homeopathic Medicinal Products from Biological Origin | pdf
Adopted April 2016
First safe dilutions
- Introduction of the List of First Safe Dilutions | pdf
Adopted May 2010 - Structure of the List of First Safe Dilutions | pdf
Adopted May 2010 - Preamble to the First List of First Safe Dilutions (FSD) | pdf
Adopted November 2016 - First safe dilutions where homeopathic use is justified (Consolidated list of FSD, Lists 1-5) | pdf
Published September 2020 - Consolidated List FSD 1-5 | pdf
This is a final comprehensive document of the previous adopted list 1-5 - Fifth List of First Safe Dilutions | pdf
Adopted November 2019
Questions and answers
- Questions and Answers on First Safe Dilutions | pdf
Adopted October 2015
Overview of Comments/Further Information
- Overview of comments received on draft document "Guidance on non-clinical documentation in applications for registration of homeopathic medicinal products for human use" | pdf
Adopted November 2021 - Overview of comments on the draft document "Fifth List of First Safe Dilutions" | pdf
Adopted November 2019 - Overview of comments on the draft document "Fourth List of First Safe Diluitions" | pdf
Adopted November 2018 - Overview of comments received on draft document "Third List of First Safe Dilutions (FSD) | pdf
Adopted December 2017 - Overview of comments received on draft document "Second List of First Safe Dilutions (FSD)" | pdf
Adopted June 2017 - Overview of comments received on draft documents "Preamble to the First List of First Safe Dilutions (FSD)" and "First List of First Safe Dilutions" | pdf
Adopted November 2016 - Overview of comments received on Question and Answer document: Issue 1-5 | pdf
Adopted May 2015 - Overview of comments received on Question and Answer document: Issue 6| pdf
Adopted June 2015 - Compilation of comments received from public consultation (2012) on FSD assessments | pdf
Published August 2014
Overview of comments
- Template for overview of comments received on draft document | doc
Adopted November 2013
First Safe Dilutions AR
- First Safe Dilutions AR Template | pdf
Adopted May 2010